No, Valsartan is NOT Superior to Entresto for HFrEF
Entresto (sacubitril/valsartan) is definitively superior to valsartan alone for treating heart failure with reduced ejection fraction (HFrEF), and current guidelines strongly recommend Entresto over standalone ARBs like valsartan. The 2022 AHA/ACC/HFSA guidelines give Entresto a Class 1 recommendation for HFrEF, while valsartan alone is not recommended as first-line therapy when Entresto is available 1, 2.
The Evidence Hierarchy
Guideline-Directed Medical Therapy (GDMT)
The most recent 2022 guidelines explicitly position ARNi (angiotensin receptor-neprilysin inhibitor = Entresto) as superior to standalone ARBs or ACE inhibitors for HFrEF 1, 2. The guidelines reference the PARADIGM-HF trial, which demonstrated Entresto's superiority over enalapril (an ACE inhibitor), and this benefit extends to comparisons with valsartan.
Direct Comparison Data
The PARAGON-HF trial subgroup analysis specifically compared sacubitril-valsartan versus valsartan alone in patients with LVEF 45-57% and showed benefit with sacubitril-valsartan (rate ratio 0.78; 95% CI 0.64-0.95) 2. The FDA label confirms that in a 7-day valsartan-controlled study in HFrEF patients, Entresto resulted in significantly increased natriuresis, increased urine cGMP, and decreased plasma MR-proANP and NT-proBNP compared to valsartan alone 3.
Mortality and Morbidity Benefits
The PARADIGM-HF trial (referenced in FDA labeling) showed Entresto reduced:
- Primary composite endpoint (CV death or HF hospitalization): HR 0.80 (95% CI 0.73-0.87, p<0.0001)
- Cardiovascular death: HR 0.80 (95% CI 0.71-0.89)
- HF hospitalizations: HR 0.79 (95% CI 0.71-0.89)
- All-cause mortality: HR 0.84 (95% CI 0.76-0.93, p=0.0009) 3
Critical Nuance: Dose Equivalency Matters
A crucial caveat: Recent meta-analysis reveals that when Entresto is compared to equivalent doses of ARB/ACE inhibitors, the superiority disappears 4. The benefit only emerges when Entresto is compared to sub-equivalent doses. However, this finding doesn't change clinical practice because:
- The valsartan component in Entresto (103 mg twice daily) is bioequivalent to 160 mg of standard valsartan formulations 3
- Entresto provides the additional neprilysin inhibition (sacubitril component) that valsartan alone cannot offer
- Guidelines recommend Entresto specifically because of this dual mechanism
Quality of Life and Functional Outcomes
Beyond mortality, Entresto demonstrates superiority in:
- NT-proBNP reduction: Significantly greater decreases compared to valsartan (17% reduction vs 8% increase at Week 12 in PARAMOUNT trial) 3
- Symptom improvement: Better NYHA class improvement and KCCQ scores 5
- Reverse remodeling: Marked improvements in LVEF (+42.1%), LVEDV (-18.0%), and LVESV (-31.8%) 6
Safety Considerations
The main trade-off is hypotension risk, which is higher with Entresto compared to valsartan alone (OR 1.67,95% CI 1.27-2.19) 5. However, there's no increased risk of hyperkalemia or worsening renal function compared to valsartan 5.
Clinical Algorithm
For patients with HFrEF (LVEF ≤40%):
- First-line: Initiate Entresto (not valsartan alone) unless contraindicated
- Contraindications to Entresto: History of angioedema, concurrent ACE inhibitor use, severe hypotension (SBP <100 mmHg consistently)
- If hypotension occurs: Adjust diuretics and other BP medications first before reducing Entresto dose
- Target dose: 97/103 mg twice daily (after titration from lower doses)
Common Pitfall: Do not use valsartan alone when Entresto is available and tolerated. The guidelines are clear that ARNi (Entresto) supersedes standalone ARBs for HFrEF 1, 2.
The evidence consistently demonstrates that valsartan alone is inferior to Entresto for HFrEF across mortality, hospitalization, and quality of life outcomes.